# Somatostatin receptor 2

Source: https://nuclide.cc/targets/sstr2/  
Nuclide record `sstr2` (Target). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Somatostatin receptor 2 is a hormone receptor densely present on neuroendocrine tumours, and was the first theranostic target to reach routine care.

## Summary

Somatostatin receptor 2 is a G-protein-coupled receptor overexpressed on well-differentiated neuroendocrine tumours, which internalise bound somatostatin analogues and so can be both imaged and treated with the same peptide. 68Ga-DOTATATE PET (Netspot) and 177Lu-DOTATATE (Lutathera, NETTER-1 and NETTER-2) established the theranostic paradigm, in which a diagnostic scan selects patients for a matched radioligand. SSTR PET is positive in 80-90% of well-differentiated neuroendocrine tumours but lower in grade 3, and the receptor is also expressed in meningioma, 30-50% of small-cell lung cancer, and some breast cancers. Alpha-emitting 225Ac-DOTATATE (RYZ101) and 212Pb-DOTAMTATE are in phase 3, testing whether alpha particles outperform beta. The simple version is a hormone receptor that lets doctors see and treat neuroendocrine tumours with the same molecule.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Tags: theranostic
- Symbol: SSTR2
- Class: surface-antigen
- Biology: G-protein-coupled receptor; also expressed in meningioma, small-cell lung cancer, and some breast cancers.
- Where found: Neuroendocrine tumours; Meningioma; Small-cell lung cancer (subset)

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Somatostatin_receptor_2
- Wikipedia: https://en.wikipedia.org/wiki/Somatostatin_receptor_2

## Connected records

- isotopes: [Actinium-225](https://nuclide.cc/isotopes/ac-225/), [Gallium-68](https://nuclide.cc/isotopes/ga-68/), [Lead-212](https://nuclide.cc/isotopes/pb-212/), [Lutetium-177](https://nuclide.cc/isotopes/lu-177/)
- indications: [Grade 3 well-differentiated neuroendocrine tumour](https://nuclide.cc/indications/grade-3-net/), [Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)](https://nuclide.cc/indications/hereditary-ppgl/), [Lung neuroendocrine tumours (typical and atypical carcinoid)](https://nuclide.cc/indications/lung-net/), [Metastatic pheochromocytoma and paraganglioma](https://nuclide.cc/indications/metastatic-ppgl/), [Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)](https://nuclide.cc/indications/multiple-endocrine-neoplasia/), [Neuroendocrine tumours](https://nuclide.cc/indications/neuroendocrine/), [Pancreatic neuroendocrine tumours](https://nuclide.cc/indications/pancreatic-net/), [Pheochromocytoma and paraganglioma (PPGL)](https://nuclide.cc/indications/pheochromocytoma-paraganglioma/), [Small intestinal neuroendocrine tumours](https://nuclide.cc/indications/small-intestinal-net/), [Small-cell lung cancer](https://nuclide.cc/indications/sclc/)
- companies: [ITM Isotope Technologies Munich](https://nuclide.cc/companies/itm/), [Molecular Targeting Technologies](https://nuclide.cc/companies/molecular-targeting-technologies/), [Orano Med](https://nuclide.cc/companies/orano-med/), [Perspective Therapeutics](https://nuclide.cc/companies/perspective-therapeutics/), [POINT Biopharma](https://nuclide.cc/companies/point-biopharma/), [RadioMedix](https://nuclide.cc/companies/radiomedix/)
- technologies: [Auger-electron therapy](https://nuclide.cc/technologies/auger-electron-therapy/), [Lutetium-177 radioligand therapy](https://nuclide.cc/technologies/lu177-radioligand-therapy/), [Peptide receptor radionuclide therapy (PRRT)](https://nuclide.cc/technologies/prrt/), [Radioligand plus DNA-repair inhibitor combinations](https://nuclide.cc/technologies/radionuclide-parp-combination/), [Radioligand therapy (beta emitters)](https://nuclide.cc/technologies/radioligand-therapy/), [Somatostatin receptor PET (68Ga/64Cu-DOTATATE)](https://nuclide.cc/technologies/sstr-pet/), [Targeted alpha therapy](https://nuclide.cc/technologies/targeted-alpha-therapy/)
- drugs: [177Lu-edotreotide](https://nuclide.cc/drugs/itm-11/), [212Pb-DOTAMTATE](https://nuclide.cc/drugs/alphamedix/), [Actinium-225 DOTATATE](https://nuclide.cc/drugs/ryz101/), [Copper-64 dotatate](https://nuclide.cc/drugs/cu-64-dotatate/), [Gallium-68 DOTATATE (and Cu-64 DOTATATE)](https://nuclide.cc/drugs/ga68-dotatate/), [Gallium-68 edotreotide (DOTATOC)](https://nuclide.cc/drugs/ga-68-dotatoc/), [Indium-111 pentetreotide](https://nuclide.cc/drugs/in-111-pentetreotide/), [Lead-212 VMT-alpha-NET](https://nuclide.cc/drugs/pb-212-vmt-alpha-net/), [Lutetium-177 dotatate](https://nuclide.cc/drugs/lutathera/), [Lutetium-177 dotatate (radioligand equivalent)](https://nuclide.cc/drugs/lu-177-dotatate-generic/), [Pasireotide](https://nuclide.cc/drugs/pasireotide/), [Radioactive iodine (I-131)](https://nuclide.cc/drugs/radioactive-iodine/)
- institutions: [Erasmus MC Cancer Institute](https://nuclide.cc/institutions/erasmus-mc/), [Inselspital, Bern University Hospital / University Cancer Center Inselspital](https://nuclide.cc/institutions/inselspital-bern/), [IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)](https://nuclide.cc/institutions/irst-meldola/), [Uppsala University Hospital / Uppsala University](https://nuclide.cc/institutions/uppsala-akademiska/)
- terms: [PRRT (peptide receptor radionuclide therapy)](https://nuclide.cc/terms/prrt-term/)
- trials: [COMPETE](https://nuclide.cc/trials/compete/), [NETTER-1](https://nuclide.cc/trials/netter-1/)
- pairings: [68Ga-DOTATATE PET before Lutathera (177Lu-DOTATATE)](https://nuclide.cc/pairings/ga68-dotatate-then-lutathera/), [SSTR PET → PRRT](https://nuclide.cc/pairings/sstr-pet-to-prrt/)
- roadmaps: [Dosimetry roadmap: MIRD schema → fixed dosing → personalised, image-based dose](https://nuclide.cc/roadmaps/dosimetry-roadmap/), [Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET](https://nuclide.cc/roadmaps/molecular-imaging-roadmap/), [Neuro-oncology imaging roadmap: FDG PET → amino acid PET → SSTR2 theranostics in meningioma](https://nuclide.cc/roadmaps/neuro-imaging-roadmap/), [Radiopharmaceutical roadmap: iodine → lutetium → actinium](https://nuclide.cc/roadmaps/radiopharma-roadmap/), [SSTR theranostics roadmap: octreotide scintigraphy → 68Ga-DOTATATE → 177Lu-DOTATATE → alpha](https://nuclide.cc/roadmaps/sstr-theranostics-roadmap/)
- ideas: [SSTR antagonist radioligands to increase tumour dose](https://nuclide.cc/ideas/idea-net-antagonist-ligands/)
- people: [Emily K. Bergsland](https://nuclide.cc/people/emily-bergsland/), [Jonathan R. Strosberg](https://nuclide.cc/people/jonathan-strosberg/), [Simron Singh](https://nuclide.cc/people/simron-singh/)
- key papers: [NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours](https://nuclide.cc/key-papers/paper-netter-2-lancet-2024/)
- opportunities: [An inflammation tracer that does not need a diet](https://nuclide.cc/opportunities/opp-cardiac-sarcoidosis-specific-tracer/)

---
JSON: https://nuclide.cc/api/v1/entities/sstr2.json